Tony Kouzarides is passionate about ecosystems: well-balanced communities that flourish on mutual and dynamic interactions. But the ecosystems that excite him are not made up of plants, animals and environments. They’re made up of experts.
When a drug fails late on in clinical trials it’s a major setback for launching new medicines. It can cost millions, even billions, of research and development funds. Now, an ‘adaptive’ approach to clinical trials and a genetic tool for predicting success are increasing the odds of picking a winner.
The stirrings of a revolution are starting to ripple through hundreds of laboratories. It’s a revolution that aims to result in new medicines – faster and with fewer failures – and it’s being led by three UK universities and three global pharmaceutical companies.
Researchers are working with pharmaceutical companies to make improvements across the whole supply chain, from how a pill is made to the moment it is swallowed by the patient.
Three global pharmaceutical companies and the technology transfer offices of three world-leading universities – Imperial College London, University College London and the University of Cambridge – have joined forces with a combined £40 million to create the Apollo Therapeutics Fund.
A collaboration between the University of Cambridge and MedImmune, the global biologics research and development arm of AstraZeneca, has led researchers to identify a potentially significant new application for a well-known human enzyme, which may have implications for treating respiratory diseases such as asthma.
Cambridge researchers and pharma in innovative new consortium to develop and study early stage drugs28 Jul 2015
An innovative new Consortium will act as a ‘match-making’ service between pharmaceutical companies and researchers in Cambridge with the aim of developing and studying precision medicines for some of the most globally devastating diseases.
AstraZeneca and the University of Cambridge today announced three new joint schemes to support more than 80 PhD scholarships and eight clinical lectureships over the next five years spanning translational science, basic and clinical research. Two of the schemes are co-funded by the NIHR Cambridge Biomedical Research Centre, a partnership between Cambridge University Hospitals and University of Cambridge.
A new drug for ovarian cancer, developed by researchers at the University of Cambridge and AstraZeneca, has today become the first of new class of drugs, known as PARP-inhibitors, to be granted approval anywhere in the world. The drug, Lynparza, has been granted Marketing Authorisation from the European Commission.
AstraZeneca, its global biologics research and development arm, MedImmune, and the University of Cambridge today announce four new collaborations, building on their existing partnership. The latest collaborations reinforce AstraZeneca’s commitment to research in Cambridge following the company’s decision to locate one of its three global R&D centres and its global headquarters in the city that has been home to MedImmune’s biologics research laboratories for 25 years.